Lead Product(s) : Mezagitamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Reports Positive Results from Phase 2 Mezagitamab Study
Details : TAK-079 (mezagitamab) is a fully human monoclonal antibody targeting CD38 expressing cells. It is being developed for patients with chronic primary immune thrombocytopenia (ITP).
Product Name : TAK-079
Product Type : Antibody
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Mezagitamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAK-279 is a highly selective, oral allosteric TYK2 inhibitor, which has potential to become an important treatment option in multiple immune-mediated inflammatory diseases.
Product Name : TAK-279
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable